Causes of hOCT1‐Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor‐Selective Gene Therapy

Elisa Lozano, Maria J. Monte, Oscar Briz, Angel Hernández-Hernández, Jesus M. Banales, Jose J.G. Marin, Rocio I.R. Macias, Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT). Journal of Controlled Release. ,vol. 216, pp. 93- 102 ,(2015) , 10.1016/J.JCONREL.2015.08.022

Matthias Pinter, Wolfgang Sieghart, Michael Reisegger, Friedrich Wrba, Markus Peck-Radosavljevic, Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report Wiener klinische Wochenschrift. ,vol. 123, pp. 61- 64 ,(2011) , 10.1007/S00508-010-1522-Y

Monica R Muppidi, Scott Portwood, Elizabeth A Griffiths, James E Thompson, Laurie A Ford, Craig W Freyer, Meir Wetzler, Eunice S Wang, None, Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma & Leukemia. ,vol. 15, ,(2015) , 10.1016/J.CLML.2015.02.033

Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frédéric Blanc, Andre Cosme De Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner, Myron Schwartz, Camillo Porta, Stefan Zeuzem, Luigi Bolondi, Tim F Greten, Peter R Galle, Jean-François Seitz, Ivan Borbath, Dieter Häussinger, Tom Giannaris, Minghua Shan, Marius Moscovici, Dimitris Voliotis, Jordi Bruix, None, Sorafenib in Advanced Hepatocellular Carcinoma The New England Journal of Medicine. ,vol. 359, pp. 378- 390 ,(2008) , 10.1056/NEJMOA0708857

Ilya V. Ulasov, Angel A. Rivera, Adam M. Sonabend, Adam M. Sonabend, Ming Wang, Zeng B. Zhu, Maciej S. Lesniak, Lisa B. Rivera, Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy. Cancer Biology & Therapy. ,vol. 6, pp. 679- 685 ,(2007) , 10.4161/CBT.6.5.3957

P Martinez-Becerra, J Vaquero, MR Romero, E Lozano, C Anadon, RIR Macias, MA Serrano, N Grane-Boladeras, L Munoz-Bellvis, L Alvarez, B Sangro, M Pastor-Anglada, JJG Marin, None, No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors. Molecular Pharmaceutics. ,vol. 9, pp. 1693- 1704 ,(2012) , 10.1021/MP300028A

Peter Nagi, Selwyn M Vickers, Julia Davydova, Yasuo Adachi, Koichi Takayama, Shannon Barker, Victor Krasnykh, David T Curiel, Masato Yamamoto, None, Development of a Therapeutic Adenoviral Vector for Cholangiocarcinoma Combining Tumor-Restricted Gene Expression and Infectivity Enhancement Journal of Gastrointestinal Surgery. ,vol. 7, pp. 364- 371 ,(2003) , 10.1016/S1091-255X(02)00437-7

Alexander Huether, Michael Höpfner, Viola Baradari, Detlef Schuppan, Hans Scherübl, Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma Biochemical Pharmacology. ,vol. 73, pp. 1308- 1317 ,(2007) , 10.1016/J.BCP.2006.12.031

B Lu, S K Makhija, D M Nettelbeck, A A Rivera, M Wang, S Komarova, F Zhou, M Yamamoto, H J Haisma, R D Alvarez, D T Curiel, Z B Zhu, Evaluation of tumor-specific promoter activities in melanoma Gene Therapy. ,vol. 12, pp. 330- 338 ,(2005) , 10.1038/SJ.GT.3302385

DAVID T. CURIEL, Strategies to adapt adenoviral vectors for targeted delivery. Annals of the New York Academy of Sciences. ,vol. 886, pp. 158- 171 ,(1999) , 10.1111/J.1749-6632.1999.TB09409.X